CXCR4 and non-Hodgkin lymphoma: The first clinical application of [68Ga]pentixafor PET has been carried out in patients with non-Hodgkin lymphoma and multiple myeloma, which confirmed the CXCR4 expression in these lymphoproliferative diseases as a proof-of-concept [4].